Ginkgo Bioworks Holdings (DNA) Other Non-Current Assets (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Other Non-Current Assets came in at $39.5 million in Q1 2026, down 15.51% YoY from $46.8 million in Q1 2025, and down 16.21% on a QoQ basis from $47.2 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Other Non-Current Assets data on file, last reported at $39.5 million in Q1 2026.
- Quarterly Other Non-Current Assets fell 15.51% year-over-year to $39.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.5 million (down 15.51% YoY) and the FY2025 annual result came in at $47.2 million, down 14.76% from the prior year.
- Other Non-Current Assets declined to $39.5 million in Q1 2026, from $47.2 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $97.9 million in Q2 2023 to a low of $39.5 million in Q1 2026.
- A 5-year average of $61.7 million and a median of $55.3 million in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets surged 8223.17% — and 2024, when it slumped 38.53%.
- Tracing DNA's Other Non-Current Assets over 5 years: stood at $88.7 million in 2022, then sank by 34.57% to $58.1 million in 2023, then retreated by 4.68% to $55.3 million in 2024, then decreased by 14.76% to $47.2 million in 2025, then declined by 16.21% to $39.5 million in 2026.
- The last three Other Non-Current Assets figures came in at $39.5 million (Q1 2026), $47.2 million (Q4 2025), and $46.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | 87.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 87.48 Mn |
| Mar 31, 2026 | 39.52 Mn |
| Dec 31, 2025 | 47.17 Mn |
| Sep 30, 2025 | 46.59 Mn |
| Jun 30, 2025 | 47.02 Mn |
| Mar 31, 2025 | 46.78 Mn |
| Dec 31, 2024 | 55.34 Mn |
| Sep 30, 2024 | 59.79 Mn |
| Jun 30, 2024 | 60.21 Mn |
| Mar 31, 2024 | 60.63 Mn |
| Dec 31, 2023 | 58.06 Mn |
| Sep 30, 2023 | 97.02 Mn |
| Jun 30, 2023 | 97.95 Mn |
| Mar 31, 2023 | 97.26 Mn |
| Dec 31, 2022 | 88.73 Mn |
| Sep 30, 2022 | 43.93 Mn |
| Jun 30, 2022 | 53.02 Mn |
| Mar 31, 2022 | 49.62 Mn |
| Dec 31, 2021 | 1.07 Mn |
| Sep 30, 2021 | 26.80 Mn |